JPM25: M&A strategist GSK acquires IDRX for $1B upfront

2 days ago · JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care. By Gabrielle Masson Jan 13, 2025 2:00am. GSK biotech deals M&A …

$1
OFF

JPM25: M&A Strategist GSK Acquires IDRX For $1B Upfront

2 weeks from now

2 days ago · JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care. By Gabrielle Masson Jan 13, 2025 2:00am. GSK biotech deals M&A …

fiercebiotech.com

$1.15
OFF

JP Morgan 2025: GSK Acquires IDRx In $1.15bn Deal - Yahoo Finance

2 weeks from now

2 days ago · JP Morgan 2025: GSK acquires IDRx in $1.15bn deal The deal includes an upfront payment of $1bn and an additional $150m tied to regulatory milestones. Credit: Bloomberg via …

yahoo.com

$1
OFF

GSK Targets Rare Cancer With $1B+ Acquisition Of IDRx

2 weeks from now

2 days ago · GSK fired the opening gun for the 2025 JP Morgan Healthcare Conference on Monday with a front-loaded acquisition agreement, moving to buy precision therapy specialist …

biospace.com

$1.15
OFF

GSK To Acquire IDRx For $1.15bn — Financier Worldwide

2 weeks from now

2 days ago · Drug manufacturer GSK has agreed to acquire US biopharmaceutical firm IDRx, which is developing a therapy for the treatment of gastrointestinal stromal tumours (GIST). …

financierworldwide.com

$1.15
OFF

GSK Enters Agreement To Acquire IDRx For $1.15 Billion To …

2 weeks from now

2 days ago · UK pharmaceutical giant GSK has confirmed that it has signed an agreement to acquire the privately-held biotechnology company IDRx. Under the terms of the agreement, …

nairametrics.com

53%
OFF

GSK To Buy US-Based Stomach Cancer Drug Developer For Over

2 weeks from now

2 days ago · GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.

benzinga.com

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion - U.S. News

2 weeks from now

3 days ago · (Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a …

usnews.com

$1
OFF

GSK Acquires IDRx For $1B, Gaining Breakthrough GIST Cancer …

2 weeks from now

2 days ago · GSK has announced the acquisition of IDRx, a clinical-stage biopharmaceutical company, for $1 billion upfront plus a potential $150 million regulatory milestone payment.The …

stocktitan.net

$1
OFF

GSK Nears $1bn Deal For Biotech Developing Drug For Rare Tumour

2 weeks from now

Jan 8, 2025 · GSK is nearing a $1bn deal to buy a US biotech developing a treatment for rare gastrointestinal tumours, as the UK drugmaker races to expand its oncology business.

ft.com

$1
OFF

Is GSK Prepping A $1bn Takeover Bid For IDRx? | Pharmaphorum

2 weeks from now

6 days ago · GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted ... The proceeds were earmarked for the ongoing phase 1/1b StrateGIST 1 trial of the selective …

pharmaphorum.com

$1
OFF

JPM25: GSK's CSO Shares Science Strategy Behind Deal-heavy Year

2 weeks from now

18 hours ago · JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care The most optimal deals are “all about target finding” and “matching …

fiercebiotech.com

$1.15
OFF

GSK To Buy Precision Therapeutics Firm IDRx For Up To USD1.15 Billion

2 weeks from now

2 days ago · (Sharecast News) - GSK on Monday said it was buying US-based biopharmaceutical company IDRx for up to $1.15bn. 10 Jan 2025 08:58 GSK awaits FDA review of new shingles …

lse.co.uk

$1
OFF

GSK Confirms Plan To Buy Cancer Firm IDRx For $1bn

2 weeks from now

2 days ago · IDRX-42 is currently in the phase 1/1b StrateGIST 1 trial in patients with KIT-mutant GIST who have failed prior treatment with Novartis Gleevec/Glivec (imatinib mesylate) and …

pharmaphorum.com

$1
OFF

GSK Acquires IDRx And Its Rare Cancer Drug For $1B Upfront

2 weeks from now

2 days ago · Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held biotech IDRx for $1 billion upfront, bringing a rare cancer …

endpts.com

$1
OFF

GSK Boosts Cancer Drug Pipeline With $1B Acquisition Of IDRx

2 weeks from now

2 days ago · London: In a strategic move to enhance its cancer drug portfolio, GlaxoSmithKline (GSK) has entered into an agreement to acquire Boston-based clinical-stage …

indiatimes.com

$1
OFF

GSK In Talks To Buy U.S. Rare Tumor Specialist IDRx For Up To $1 ...

2 weeks from now

6 days ago · --Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 …

morningstar.com

$1
OFF

GSK Is Said To Be Nearing $1B Deal To Acquire U.S. Biotech IDRx

2 weeks from now

British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout deal to acquire IDRx, a U.S. biotech focused on developing drugs for rare gastrointestinal tumors, The Financial Times …

msn.com

$1
OFF

GSK Is Said To Be Nearing $1B Deal To Acquire U.S. Biotech IDRx

2 weeks from now

Jan 8, 2025 · British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout deal to acquire IDRx, a U.S. biotech focused on developing drugs for rare gastrointestinal tumors, The …

seekingalpha.com

FAQs about JPM25: M&A strategist GSK acquires IDRX for $1B upfront Coupon?

Does GSK buy idrx?

Credit: Bloomberg via Getty Images. ·Pharmaceutical Technology·Bloomberg via Getty Images. GSK has announced a definitive agreement to acquire IDRx, a US-based biotechnology company specialising in treatments for gastrointestinal cancers, for up to $1.15bn in cash, marking the first deal of the 2025 JP Morgan Healthcare Conference. ...

Who owns idrx biotech?

A clinical-stage biotech founded in 2022, IDRx has private equity firm Blackstone (BX) and venture capital firms Andreessen Horowitz and RA Capital among its notable investors. Its initial product candidate, IDRX-42, targets gastrointestinal stromal tumor (GIST), a GIT cancer that affects an estimated 4,000–6,000 Americans every year. ...

Does idrx stop tumours from growing?

IDRx’s experimental drug has shown early signs of addressing this problem. In a phase-one trial on patients that had already tried two other treatments that had stopped working, the IDRx drug stopped their tumours from growing for 12.9 months. ...

Can idrx treat gastrointestinal stromal cancer?

IDRx is conducting early-stage trials of its targeted therapy for patients with a type of cancer called gastrointestinal stromal tumour, or Gist, which affects between 4,000 and 6,000 people each year in the US. The available treatments for Gist are not very effective because of resistance mutations in the cancer in 80 per cent of cases. ...

Does idrx-42 target gastrointestinal stromal tumor?

Its initial product candidate, IDRX-42, targets gastrointestinal stromal tumor (GIST), a GIT cancer that affects an estimated 4,000–6,000 Americans every year. The U.S. FDA has granted orphan drug designation and fast-track designation for IDRX-42 in GIST. ...

How did GSK perform in the first three quarters of 2024?

Sales of cancer drugs at GSK increased 94 per cent year on year to more than $1bn in the first three quarters of 2024. This included a contribution from the drug Ojjaara, which the company acquired as part of its $1.7bn purchase of Sierra Oncology in 2022. ...